8-chloro-2-[(1E,3E,5E,7E)-2,6-dimethyl-8-(2,6,6-trimethylcyclohexen-1-yl)octa-1,3,5,7-tetraenyl]-4,4-dimethyl-1,2-dihydro-[1,3]oxazino[5,4-b]quinoline | 1615680-58-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 8-chloro-2-[(1E,3E,5E,7E)-2,6-dimethyl-8-(2,6,6-trimethylcyclohexen-1-yl)octa-1,3,5,7-tetraenyl]-4,4-dimethyl-1,2-dihydro-[1,3]oxazino[5,4-b]quinoline
• CAS: 1615680-58-4
• 化学式: C₃₂H₃₉ClN₂O
• 分子量: 503.127
• InChiKey: ICJFGGNAFMYMND-YQPAFZHESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.2
• 重原子数：
  36
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  34.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-(3-amino-6-chloroquinolin-2-yl)propan-2-ol 、 视黄醛 以 苯 为溶剂， 反应 1.0h， 生成 2-(6-chloro-((3-((E)-2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenylidene)amino)quinolin-2-yl)propan-2-ol 、 8-chloro-2-[(1E,3E,5E,7E)-2,6-dimethyl-8-(2,6,6-trimethylcyclohexen-1-yl)octa-1,3,5,7-tetraenyl]-4,4-dimethyl-1,2-dihydro-[1,3]oxazino[5,4-b]quinoline
  参考文献：
  名称：

  [EN] PERI-CARBINOLS
  [FR] PÉRI-CARBINOLS

  摘要：

  本发明涉及式(I)化合物：药物组合物和治疗、减轻黄斑变性症状或减少黄斑变性风险的使用方法。

  公开号：

  WO2014100425A1

文献信息

• ALDEHYDE CONJUGATES AND USES THEREOF
  申请人：Aldeyra Therapeutics, Inc.

  公开号：US20200246345A1

  公开（公告）日：2020-08-06

  The present invention provides compounds and methods of use thereof for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

  本发明提供了化合物及其使用方法，用于治疗、预防和/或减少由醛毒性引起病理发生的疾病、紊乱或状况的风险，包括眼部疾病、皮肤疾病、与水泡剂引起的有害效应相关的状况，以及自身免疫、炎症、神经和心血管疾病，通过使用一种主要胺来清除有毒醛类化合物，如MDA和HNE。
• PERI-CARBINOLS
  申请人：ALDEXA THERAPEUTICS, INC.

  公开号：US20150344432A1

  公开（公告）日：2015-12-03

  The present invention is directed to compounds of formula(I): pharmaceutical compositions, and methods of use for treating, reducing a symptom of or reducing the risk of macular degeneration.

  本发明涉及式(I)化合物：制药组合物和用于治疗、减轻症状或减少黄斑变性风险的方法。
• US9604997B2
  申请人：——

  公开号：US9604997B2

  公开（公告）日：2017-03-28
• [EN] ALDEHYDE CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS D'ALDÉHYDE ET LEURS UTILISATIONS
  申请人：ALDEYRA THERAPEUTICS INC

  公开号：WO2017035082A1

  公开（公告）日：2017-03-02

  The present invention provides compounds and methods of use thereof for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
• [EN] PERI-CARBINOLS<br/>[FR] PÉRI-CARBINOLS
  申请人：ALDEXA THERAPEUTICS INC

  公开号：WO2014100425A1

  公开（公告）日：2014-06-26

  The present invention is directed to compounds of formula(I): pharmaceutical compositions, and methods of use for treating, reducing a symptom of or reducing the risk of macular degeneration.

  本发明涉及式(I)化合物：药物组合物和治疗、减轻黄斑变性症状或减少黄斑变性风险的使用方法。